Aside from validity of Inmed's patent claims (as being sufficiently novel in accordance with patent law), is one method preferable than the other for applications considered? Or is it simply six in one, half dozen in the other...
The product is always expressed outside of the ecoli cells. InMed has been studying cannabinoid effects in vivo on animals, I haven’t seen anything about InMed’s method being purely in vivo. They compared they method to that of modern insulin production in ecoli which is basically what Full Spectrum already has and some.
Hey, I’m merely trying to discuss this and voice my words of caution. Not pumping / dumping, I don’t have enough capital to even make a difference lol.
News 
Market Data 
Discover 
